Clinical Trial Update: Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa [Phase 3]

View source ↗

Summary

Phase III trial update for miltefosine/paromomycin in treating visceral leishmaniasis in Eastern Africa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Visceral Leishmaniasis

Drugs mentioned

• Miltefosine/Paromomycin

Snippet

Sponsor: Drugs for Neglected Diseases | Conditions: Visceral Leishmaniasis | Phase 3 | Status: COMPLETED